cetuximab Apr 9, 2020 FDA Approves Braftovi, Erbitux Combination for BRAF V600E-Mutated Colorectal Cancer Patients Nov 7, 2019 Colorectal Cancers Dial up Mutability in Response to Targeted Treatments Sep 24, 2019 Certain BRAF Mutations May Indicate Tumors More Likely to Respond to Anti-EGFR Therapy Premium Jul 9, 2019 BEACON Trial Reports Survival Benefit for Triple Targeted Treatment in BRAF-Mutated Metastatic CRC Jun 6, 2019 TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts Premium Oct 4, 2017 BioMarker Strategies Wins NCI Grant to Develop Head and Neck Cancer CDx Dec 15, 2016 Prospective Study Supports Liquid Biopsy Monitoring of Colorectal Cancer Drug Response Premium May 13, 2016 Colorectal Cancer Patients' Cetuximab Response Can Be Discerned From FCGR2A Genotype Premium Breaking News California Governor Vetoes Biomarker Test Coverage Bill Massive Bio, Perthera Partner on Biomarker-Based Clinical Trial Matching Autolus Therapeutics, BMS Partner to Develop Cell Therapies Equipped With Safety Switches Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients Seneca Therapeutics Cleared by FDA to Start Phase I/II Oncolytic Virus Trial
